Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Frontline Treatment in Patients With IDH-Mutated AML Unfit for Intensive Chemotherapy

February 28th 2023

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

Practical Advice on the Management of Tumor Lysis Syndrome

February 28th 2023

Closing out his discussion on tumor lysis syndrome, Anthony Perissinotti, PharmD, BCOP, shares practical advice on its identification and management.

New Approvals Continue to Shift Treatment Landscape in Hematologic Malignancies

February 27th 2023

Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.

Dr. Beitinjaneh on the Evaluation of Tabelecleucel in EBV+ Hematologic Malignancies

February 27th 2023

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

Progress in Disease Detection Sets the Stage for MRD’s Role in AML

February 27th 2023

For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.

Dr. Sauter on Questions Surrounding Novel Therapies in Hematologic Malignancies

February 24th 2023

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Dr. Wang on Contraindications to Hypomethylating Therapy in Older Patients With AML

February 24th 2023

Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Dr. Amandeep Salhotra on the Efficacy and Safety of Orca-Q in GVHD

February 24th 2023

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.

Dr. Cortes on Better Understanding Areas of Interest in ALL

February 24th 2023

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Emerging Therapies for Lower-Risk MDS

February 24th 2023

Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.

Luspatercept in Lower-Risk MDS

February 24th 2023

Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.

First- and Second-Line Treatment Options in Lower-Risk MDS

February 24th 2023

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Additional Updates in Second-Line Treatment of Lower-Risk MDS

February 23rd 2023

Experts summarize recent updates on other approved or emerging second-line therapies for lower-risk MDS.

MEDALIST Trial Updates: ASH 2022 and EHA 2022

February 23rd 2023

Dr Komrokji presents key data updates from the MEDALIST trial on luspatercept in patients with lower-risk MDS that were presented at the 2022 European Hematology Association (EHA) Congress and the 2022 ASH Annual Meeting.

Tumor Lysis Syndrome: Treatment Armamentarium

February 21st 2023

Guideline-directed treatment strategies available to patients with identified tumor lysis syndrome.

Acute Myeloid Leukemia: VEN + AZA Treatment in Patients Unfit for Intensive Chemotherapy

February 21st 2023

A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.

Tumor Lysis Syndrome: Prophylactic Strategies

February 21st 2023

An overview of the prophylactic strategies that may be utilized to reduce the likelihood of tumor lysis syndrome.

Optimizing Management of TP53-Mutated Acute Myeloid Leukemia

February 21st 2023

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

Vedolizumab Plus Standard Prophylaxis Reduces Rate of Lower GI aGVHD

February 19th 2023

The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.